RadiotypeDX is currently undergoing external validation, using tissue and clinical data from a randomized controlled trial evaluating post-operative RT after breast-conserving surgery in patients with early BC, who received appropriate adjuvant systemic therapy according to ER status (80). This evidence concerns the gene ESR1 and breast cancer.